Inadequate testing and protracted delays in producing results have crippled tracking and hampered efforts to contain major outbreaks.
The nation’s leading infectious disease expert tells biotech executives that Covid-19 has inflicted global damage, exposing worrisome racial disparities.
Remdesivir was shipped to small hospitals even as besieged medical centers were denied access.
The drug failed as a treatment for hepatitis and Ebola. With federal funding, scientists trained it on the coronavirus.
A panel of experts said there was insufficient evidence about many drugs that have been considered as possible remedies for coronavirus patients, including some President Trump has advocated.
Doctors and patients also worry that the president’s rosy outlook for the treatments will exacerbate shortages of old malaria drugs relied on by patients with lupus and other debilitating conditions.